Login

CDK9-IN-7

CAT:
804-HY-126251-05
Size:
50 mg
Price:
Ask
For price, please contact [email protected]
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
CDK9-IN-7 - image 1

CDK9-IN-7

  • CAS Number: 2369981-71-3
  • UNSPSC Description: CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC[1].
  • Target Antigen: Apoptosis; CDK
  • Type: Reference compound
  • Related Pathways: Apoptosis;Cell Cycle/DNA Damage
  • Field of Research: Cancer
  • Assay Protocol: https://www.medchemexpress.com/cdk9-in-7.html
  • Purity: 98.05
  • Solubility: DMSO : 62.5 mg/mL (ultrasonic)
  • Smiles: O=C(N(C)C)C1=CC2=CN=C(NC3=CC=C(NC(CCCCCCCN=C=S)=O)C=C3)N=C2N1C4CCCC4
  • Molecular Weight: 547.71
  • References & Citations: [1]Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535.
  • Shipping Conditions: Room Temperature
  • Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information: No Development Reported